GlassScriptPhysician profile
John L Roussalis
NPI 1235252669
$13,241.85
in general payments reported to CMS, 2019-2025
28 companies · $4,860 in 2025
The $4,860 reported for 2025 was more than what 92% of Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,200 · 2020: $29.75 · 2021: $105 · 2022: $90.16 · 2023: $634 · 2024: $4,323 · 2025: $4,860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $7,000 · Food and Beverage: $2,467 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $7,000.00 |
| Food and Beverage | $2,467.12 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $8,225.35 | 2022-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Allergan, INC. | $2,912.30 | 2019-2021 | |
| Becton, Dickinson and Company | $350.00 | 2024 | |
| Janssen Biotech, INC. | $256.87 | 2022-2024 | Tremfya, Remicade, Simponi |
| Convatec INC. | $206.69 | 2023-2025 | |
| Ucb, INC. | $162.24 | 2019-2025 | Bimzelx |
| Smith+Nephew, INC. | $155.39 | 2023-2025 | Collagenase Santyl |
| Incyte Corporation | $153.56 | 2023-2025 | Opzelura |
| Lilly USA, LLC | $104.88 | 2019-2023 | Taltz, Olumiant |
| Regeneron Healthcare Solutions, INC. | $86.44 | 2019-2020 | |
| Sientra, INC. | $71.12 | 2021-2022 | |
| Celgene Corporation | $64.18 | 2019 | |
| Sun Pharmaceutical Industries INC. | $49.50 | 2019-2023 | Absorica Ld, Winlevi, Ilumya |
| Leo Pharma INC. | $45.62 | 2019-2025 | Adbry |
| Organon LLC | $41.57 | 2025 | Nexplanon |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanos Medical | $38.20 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $35.54 | 2019-2024 | Siliq |
| Amgen INC. | $34.14 | 2023-2024 | Otezla |
| Abbvie INC. | $32.45 | 2023 | Botox, Natrelle Saline-Filled Breast Implants |
| Tela Bio, INC. | $29.68 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $29.00 | 2023 | Seglentis |
| Organogenesis INC. | $27.19 | 2022 | |
| Mimedx Group, INC. | $26.32 | 2024 | |
| Merz North America, INC. | $26.10 | 2025 | |
| Journey Medical Corporation | $23.95 | 2023 | |
| Medtronic, INC. | $23.54 | 2024 | V-Loc 180 |
| Genzyme Corporation | $17.19 | 2024 | |
| Triad Life Sciences INC. | $12.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Roussalis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.